Abstract: Designing a robust interface between a thermonuclear plasma and the solid material environment remains a major challenge for next-step fusion devices and future power fusion reactors.
CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB). The results are based on the final analyses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback